LNWWM
DGX icon

Laird Norton Wetherby Wealth Management’s Quest Diagnostics DGX Stock Holding History

Laird Norton Wetherby Wealth Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$376K Buy
1,971
+133
+7% +$23.6K 0.02% 674
2025
Q2 		$330K Buy
+1,838
New +$319K 0.01% 689
2024
Q4 		$305K Sell
2,021
-50
-2% -$7.78K 0.01% 695
2024
Q3 		$322K Sell
2,071
-19
-0.9% -$2.84K 0.01% 704
2024
Q2 		$286K Buy
2,090
+278
+15% +$38.1K 0.01% 729
2024
Q1 		$241K Buy
1,812
+34
+2% +$4.41K 0.01% 811
2023
Q4 		$245K Sell
1,778
-123
-6% -$16.2K 0.01% 793
2023
Q3 		$232K Sell
1,901
-124
-6% -$16.5K 0.01% 770
2023
Q2 		$285K Sell
2,025
-158
-7% -$21.8K 0.02% 738
2023
Q1 		$309K Buy
2,183
+66
+3% +$9.44K 0.02% 692
2022
Q4 		$331K Buy
2,117
+9
+0.4% +$1.29K 0.02% 649
2022
Q3 		$259K Sell
2,108
-217
-9% -$28.6K 0.02% 705
2022
Q2 		$309K Sell
2,325
-922
-28% -$126K 0.02% 669
2022
Q1 		$444K Sell
3,247
-230
-7% -$32.1K 0.03% 560
2021
Q4 		$602K Sell
3,477
-27
-0.8% -$4.11K 0.03% 459
2021
Q3 		$509K Sell
3,504
-67
-2% -$9.8K 0.03% 503
2021
Q2 		$471K Buy
3,571
+150
+4% +$19.6K 0.03% 533
2021
Q1 		$439K Sell
3,421
-773
-18% -$95.3K 0.03% 477
2020
Q4 		$500K Buy
4,194
+623
+17% +$75.9K 0.03% 461
2020
Q3 		$408K Sell
3,571
-250
-7% -$29.5K 0.04% 427
2020
Q2 		$436K Sell
3,821
-361
-9% -$38.3K 0.04% 391
2020
Q1 		$336K Buy
4,182
+1,197
+40% +$124K 0.04% 418
2019
Q4 		$319K Buy
2,985
+144
+5% +$15K 0.03% 526
2019
Q3 		$304K Buy
2,841
+158
+6% +$16.2K 0.03% 542
2019
Q2 		$273K Buy
2,683
+378
+16% +$36.3K 0.03% 568
2019
Q1 		$207K Buy
+2,305
New +$200K 0.03% 614
2018
Q4 		– Sell
-2,093
Closed -$226K – 653
2018
Q3 		$226K Sell
2,093
-45
-2% -$4.94K 0.03% 583
2018
Q2 		$235K Buy
+2,138
New +$223K 0.03% 548

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Laird Norton Wetherby Wealth Management's DGX Position: Q3 2025 in Review

Laird Norton Wetherby Wealth Management increased its Quest Diagnostics (DGX) stake by 7.2% in Q3 2025, buying an estimated $23.6K and bringing the position to 1,971 shares worth $376K. The position accounts for 0.02% of the portfolio, ranked #674.

Laird Norton Wetherby Wealth Management first reported a position in DGX in Q2 2018 and has held it in 28 quarters since. The position peaked at $602K in Q4 2021. 1,006 funds tracked by Wall St. Rank hold DGX as of Q3 2025.

  • Laird Norton Wetherby Wealth Management held 1,971 shares of Quest Diagnostics worth $376K as of Q3 2025.
  • Laird Norton Wetherby Wealth Management bought 133 Quest Diagnostics shares in Q3 2025, an estimated $23.6K.
  • Quest Diagnostics made up 0.02% of Laird Norton Wetherby Wealth Management's portfolio in Q3 2025, its #674 holding.
  • Laird Norton Wetherby Wealth Management first reported a position in Quest Diagnostics in Q2 2018 and has held it in 28 quarters since.
  • Laird Norton Wetherby Wealth Management's Quest Diagnostics position peaked at $602K in Q4 2021.
  • 1,006 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2025.

Based on Laird Norton Wetherby Wealth Management's 13F filing for Q3 2025, filed 14 Nov 2025.